Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, July 9-10, 2024, in Boston, and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference, July 15, 2024.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

Media and Investor Inquiries: Andrea Christopher Corporate Communications and Investor Relations, Aurinia achristopher@auriniapharma.com ir@auriniapharma.com

Aurinia Pharmaceuticals (NASDAQ:AUPH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024 Aurinia Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Aurinia Pharmaceuticals (NASDAQ:AUPH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024 Aurinia Pharmaceuticals 차트를 더 보려면 여기를 클릭.